Loading company…
SecreTech develops biomarkers, cellular exosome research, and proteomic analysis services.
Founded in 2023 and based in Shanghai, China, SecreTech develops biomarkers and cellular exosomes. Its antibody affinity-based proteomic platform analyzes low-abundance proteins in plasma and other samples, including protein complexes, exosomes, and cells. In January 2024, it raised angel funding led by Shanghai Healthcare Capital, with participation from Bio Venture, Sinan Yuanke, and Sino-Singapore Suzhou Industrial Park Industrial Investment.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in